Dr. O'Connor on Real-World Results With Regorafenib in mCRC

Video

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

In a presentation of the final results from the prospective, observational CORRELATE study at the 2018 ESMO Congress, real-world dosing data were revealed for regorafenib in patients with mCRC. Of the 1037 patients eligible for evaluation, results indicated that 57% started treatment at 160 mg, 30% of patients began at 120 mg, and 13% began at ≤80 mg.

The take-home message of the study, says O’Connor, is that despite the differences in starting dose, there was no impact on the median overall survival and median progression-free survival. Moving forward, it is important to consider data from the real-world setting, states O’Connor, as there may be differences in the data demonstrated in clinical trials versus the clinic.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD